Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 3/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 2/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | PLK4 | O00444 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 3/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27224625 | 0.91 | NUDT1 (0.34) | NUDT1MAPK14MAPK13DHODHMAP2K1 | |
| SCHEMBL23694100 | 0.89 | CSF1R (0.40) | NUDT1DHODHCSF1RMAP2K1 | |
| SCHEMBL23694097 | 0.88 | MAP2K1 (0.39) | MAP2K1 | |
| SCHEMBL24849644 | 0.87 | NUDT1 (0.33) | NUDT1DHODHTGFBR1CSF1RPLA2G2A | |
| SCHEMBL30459905 | 0.82 | MAP2K1 (0.35) | NUDT1MAPK14MAPK13DHODHTGFBR1 | |
| SCHEMBL23673990 | 0.82 | MAP2K1 (0.35) | NUDT1MAPK14MAPK13DHODHTGFBR1 | |
| SCHEMBL23673873 | 0.81 | MAP2K1 (0.35) | NUDT1MAPK14MAPK13DHODHTGFBR1 | |
| SCHEMBL24849056 | 0.80 | MAPT (0.42) | — | |
| SCHEMBL31236928 | 0.80 | MAPT (0.42) | — | |
| SCHEMBL28821048 | 0.80 | GAA (0.34) | NUDT1MAPK14MAPK13DHODHPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725941-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-04-15 | — | — | EP | disclosed |
| CN-115803024-B | Compositions comprising aryl amide derivatives | 中外制药株式会社 | 2025-01-10 | — | — | CN | disclosed |
| CN-114929669-B | Aryl amide derivatives with antitumor activity | 中外制药株式会社 | 2024-11-29 | — | — | CN | disclosed |
| EP-4375273-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| CN-117677607-A | Process for producing aryl amide derivative | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20230270730-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-08-31 | — | — | US | disclosed |
| EP-4186506-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-31 | — | — | EP | disclosed |
| CN-115803024-A | Composition comprising arylamide derivatives | 中外制药株式会社 | 2023-03-14 | — | — | CN | disclosed |
| US-20230002333-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-05 | — | — | US | disclosed |
| CN-114929669-A | Arylamide derivatives having antitumor activity | 中外制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270730-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | BRAF, NRAS, KRAS | NUDT1 2804/4885MAPK14 16/4885MAPK13 15/4885 |
| US-20230002333-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | BRAF, NRAS, KRAS | NUDT1 3456/4885MAPK14 47/4885MAPK13 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.